Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Background Information:
The first selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase domain.
Reference:
1. Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park). 2010 Apr 30;24(5):392-9. Review. Review. Japanese.
2. Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Review.
3. Funato T, Takeda M. [Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests]. Rinsho Byori. 2010 Feb;58(2):169-74.
APIM050154: GEFITINIB
CAS No.: 184475-35-2.
Molecular Formula: C22H24ClFN4O3.
Molecular Weight: 446.9.
Purity: > 99% (HPLC).
QC: 1HNMR, HPLC.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Copyright © 2009-2022 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.